As the regulator, certainly, our priority is to make sure that as orphan drugs are being developed they come to Canada. We want to see sites in Canada for clinical trials so that patients can have access through that, and so practitioners can become familiar with the products. Also, when a company is ready to file for a market authorization, whether they're planning to file to the U.S. or the European Union, we want them file to Canada at the same time. That is the first step in access. It's to get those products through the approval system.
After that, of course, there are steps in the access chain, which we've described: the health technology assessment and also the reimbursement decisions. What we are doing within Health Canada through our regulatory review initiative is trying to bring some of those processes more into parallel rather than having them occur sequentially. Rather than an HTA proceeding after our approval, or mostly after our approval, we're trying to bring it into a parallel stream so that the regulator is working on the regulatory approval and the HTA body is working on the assessment for a funding decision at the same time, reducing some of those time lags between those. We feel that's a very important step in improving access.
Of course, there are other factors as well. Maybe my colleague Karen Reynolds could add to this.